Need help or have questions about your order? Call 510-991-8265Questions about your order? Call 510-991-8265

Sign InShop GLPs
Shop GLPs

Topical Minoxidil Side Effects: AAD-Aligned Severity Breakdown

By
Published Updated Last reviewed
9 linked public sourcesEditorial, sourcing, and corrections policy

At a glance

  • Regulatory status / Over-the-counter 2% and 5%; Rogaine 2% approved 1988, OTC since 1996 [6]
  • Reported local effects / Scalp itching and irritation occurred more often with 5% solution than with 2% solution [3][4]
  • Foam versus solution / Propylene glycol-free foam caused less local intolerance (P=.046) [5]
  • Skin absorption / About 1.4% of an applied dose [7]
  • Label stop-use list / Chest pain, rapid heartbeat, faintness, dizziness, swelling, weight gain, scalp irritation, unwanted facial hair [1][2]

What the over-the-counter labels list

Topical minoxidil 2% and 5% products are sold over the counter, and their labels are consumer Drug Facts panels rather than prescribing inserts [6][1][2]. The men's 5% solution label covers men only and the top of the scalp only, and heart disease is one of the conditions it flags before use [1]. The women's 5% foam label carries the same stop-use list and adds hair loss associated with childbirth to its exclusions [2].

Does 5% irritate more than 2%?

Two 48-week double-blind trials compared 5% solution, 2% solution and placebo, each applied twice daily [3][4]. In 393 men aged 18 to 49, 5% beat 2% on nonvellus hair count and caused more pruritus and local irritation [3]. In 381 women aged 18 to 49, 5% beat placebo on all three primary measures and drew a higher patient rating of treatment benefit than 2%, with more pruritus, irritation and hypertrichosis than 2% or placebo [4].

Does the propylene glycol-free foam irritate less?

A 24-week single-blind trial randomized 113 women to 5% foam once daily or 2% solution twice daily. Local intolerance was significantly less frequent with the foam (P=.046), particularly pruritus and dandruff [5]. The arms differed in both vehicle and dosing frequency, so the trial cannot separate the two. The foam was propylene glycol-free, while the 2% solution tested contained propylene glycol [5].

Heart-related effects, unwanted hair and pregnancy

Both labels list chest pain, rapid heartbeat, faintness and dizziness among the effects that end use, and state the product may be harmful if used when pregnant or breast-feeding [1][2]. About 1.4% of an applied topical dose is absorbed through the skin [7]. Among 1404 patients taking low-dose oral minoxidil for hair loss, hypertrichosis occurred in 15.1%, lightheadedness in 1.7% and fluid retention in 1.3% [9]; those figures describe oral minoxidil, not topical use. Unwanted facial hair is on both topical stop-use lists and was more frequent with 5% than with 2% or placebo in the women's trial [1][4][2].

Frequently asked questions

Which scalp side effects were reported with topical minoxidil 5%?
Scalp itching and irritation. In a 48-week trial of 393 men, 5% solution caused more pruritus and local irritation than 2% [3]; in a 48-week trial of 381 women, pruritus, irritation and hypertrichosis were more frequent with 5% than with 2% or placebo [4].
Is minoxidil foam gentler on the scalp than the solution?
In a 24-week trial of 113 women, 5% foam once daily caused significantly less local intolerance than 2% solution twice daily (P=.046) [5]. The foam was propylene glycol-free, but the arms also differed in dosing frequency [5].
Can topical minoxidil affect the heart?
Both labels list chest pain, rapid heartbeat, faintness and dizziness among the effects that end use [1][2]. About 1.4% of an applied topical dose is absorbed through the skin [7].
Does topical minoxidil cause unwanted facial hair?
It is on both labels' stop-use lists [1][2], and it was more frequent with 5% than with 2% or placebo in the 48-week women's trial [4].

References

  1. U.S. National Library of Medicine, DailyMed. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue prescribing information. Men's Rogaine Extra Strength minoxidil 5% topical solution, Kenvue label
  2. U.S. National Library of Medicine, DailyMed. Women's Rogaine minoxidil 5% topical foam, Kenvue prescribing information. Women's Rogaine minoxidil 5% topical foam, Kenvue label
  3. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2002;47(3):377-85. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men
  4. Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, et al. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50(4):541-53. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss
  5. Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol. 2011;65(6):1126-1134.e2. A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women
  6. Drugs@FDA: FDA-Approved Drugs. Drugs@FDA: FDA-Approved Drugs
  7. Gupta AK, Talukder M, Venkataraman M, Bamimore MA. Minoxidil: a comprehensive review. J Dermatolog Treat. 2022;33(4):1896-1906. Minoxidil: a comprehensive review
  8. Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, et al. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol. 2007;57(5):767-74. A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
  9. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, Saceda-Corralo D, Rodrigues-Barata R, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. J Am Acad Dermatol. 2021;84(6):1644-1651. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients
Evidence overview for Topical Minoxidil Side Effects: AAD-Aligned Severity Breakdown